Fibrates and Gallstone Risk

Introduction to Fibrates and Gallstone Formation

Cholestyramine at doses of 16 g per day does not appear to increase gallstone incidence, either as monotherapy or in combination with clofibrate, and should be given at least 4 hours after other medications to avoid interaction 1
The American Association for the Study of Liver Diseases recommends that fibrates be used with caution in patients with a history of gallstones, and that cholestyramine may be a suitable alternative 1

Fibrates have been used in pregnant women with severe hypertriglyceridemia after the first trimester, but safety data are limited, and decisions about fibrate use should be individualized based on the severity of maternal disease, weighing the gallstone risk against the need for triglyceride control 1
The National Kidney Foundation recommends that fenofibrate be contraindicated in patients with eGFR <30 mL/min/1.73 m², and that the combination of statins and fibrates raises the risk for rhabdomyolysis and should not be used in CKD 2, 3, 4, 5, 6

The European Association for the Study of the Liver recommends that baseline imaging (ultrasound) be obtained before initiating fibrate therapy to document absence of stones, and that renal function should be monitored before treatment, within 3 months after starting, and every 6 months thereafter 1, 7

The risk of myopathy increases significantly when fibrates are combined with statins, particularly with gemfibrozil, while fenofibrate has a lower risk, according to the American Heart Association 8, 9, 10
Extreme caution is necessary in elderly individuals when using combined therapy, as recommended by the American College of Cardiology 8, 9

In patients with rheumatoid arthritis, fibrates should be used with caution due to the low but reported risk of autoimmune adverse effects, such as thrombocytopenia and hepatitis, as noted by the European Society of Cardiology 11